Xin H G, Xie Q
Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Zhonghua Gan Zang Bing Za Zhi. 2021 Apr 20;29(4):297-300. doi: 10.3760/cma.j.cn501113-20210409-00175.
Chronic hepatitis B (CHB) virus infection remains the leading cause of hepatocellular carcinoma (HCC) in China. Oral antiviral drugs have been shown to significantly reduce the HCC risk in CHB patients, but it cannot completely eliminate the HCC occurrence. Therefore, accurate HCC risk assessment and standardized screening in CHB patients are essential for early diagnosis and improved prognosis. In recent years, medical researchers have established a variety of HCC risk prediction models for CHB patients, providing clinicians with a good assessment method. However, due to the differences in the baseline characteristics of each model when deriving and verifying the population, the applicable population and prediction effectiveness are still different, and it is difficult to achieve a "one-size-fits all" . To this end, this paper reviews the common HCC risk assessment model for CHB patients during antiviral therapy, and introduces the monitoring and screening strategies of domestic and foreign guidelines for high-risk HCC patients in order to help clinicians better manage such patients.
慢性乙型肝炎（CHB）病毒感染仍是中国肝细胞癌（HCC）的主要病因。口服抗病毒药物已被证明可显著降低CHB患者发生HCC的风险，但无法完全消除HCC的发生。因此，对CHB患者进行准确的HCC风险评估和标准化筛查对于早期诊断和改善预后至关重要。近年来，医学研究人员为CHB患者建立了多种HCC风险预测模型，为临床医生提供了良好的评估方法。然而，由于各模型在推导和验证人群时基线特征存在差异，其适用人群和预测效果仍有所不同，难以实现“一刀切”。为此，本文综述了CHB患者抗病毒治疗期间常用的HCC风险评估模型，并介绍国内外高危HCC患者指南的监测和筛查策略，以帮助临床医生更好地管理此类患者。
